Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs. The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022. The post Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline appeared first on MedCity News.
Angelini Pharma’s acquisition of Catalyst Pharmaceuticals is part of a transformation strategy focused on neurological medicines. Catalyst’s top product is Firdapse, the first FDA-approved drug for a particular rare neuromuscular disorder. The post Angelini Pharma’s $4B Acquisition Adds Rare Disease Drugs to a Global Growth Strategy appeared first on MedCity News.
Reimbursement models that align primary care with behavioral health offer low-income provider organizations serving rural Americans and other vulnerable populations an opportunity to enhance coordination and improve outcomes while generating sorely needed revenue. The post How to Align Primary Care With Behavioral Health appeared first on MedCity News.
The gap between what technology can do and how much patients trust it won’t close on its own. Here are some design decisions that build trust — and some that quietly destroy it. The post The Trust Gap in Digital Health and AI Starts With Design — Here’s How to Close It appeared first on…
States can improve efficiency, reduce administrative costs, and, most importantly, enhance the quality of health care for its members by acting in these areas. The post Improve the Medicaid Provider Experience to Enhance Health Care appeared first on MedCity News.
While CREST-2 can stand as a guideline for understanding ACS therapies in case-by-case scenarios, it’s critical that trial conclusions do not replace clinical judgment and years of previous research. The post Why CREST-2 Trial Results Should Inform, Not Replace, Clinical Judgment appeared first on MedCity News.
Two recent reports find that Medicare Advantage organizations deny prior authorization requests for long-term care hospital, inpatient rehabilitation hospital, and skilled nursing facility stays at higher rates than requests overall. When these decisions are appealed, they are frequently overturned, particularly for skilled nursing facility stays. This may cause delays for Medicare beneficiaries who are particularly…
At least, it won’t be overturned by the US Supreme Court. Endpoints reports: The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Novo Nordisk, Novartis and Boehringer Ingelheim… The…
by EMMA PAYNE Grief is expensive. In addition to the significant human impacts, research shows that bereavement leads to a 20%-30% increase in health care utilization. Grief is also common. While we may not like to talk about it, 37% of Americans are grieving a recent death. The U.S. averaged 3.26 million deaths per year…